M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 39 of 54

COMPLETED Phase 1

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

NCT00980239
COMPLETED Phase 1

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

NCT00966693
COMPLETED Phase 2

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

NCT00967369
COMPLETED NA

Mobile Smoking Cessation Intervention in Enhancing Cancer Outreach in Low-Income Adult Smokers

NCT00948129
COMPLETED Phase 1

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

NCT00954226
COMPLETED Phase 2

High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer

NCT00934128
COMPLETED

Discount Generic Prescription Study

NCT00971022
COMPLETED Phase 2

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

NCT00958256
TERMINATED Phase 1

Lenalidomide and Paclitaxel in Prostate Cancer

NCT00933426
TERMINATED Phase 2

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT00939159
COMPLETED Phase 2

Pomalidomide for Myelofibrosis Patients

NCT00946270
COMPLETED

Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing

NCT00909207
COMPLETED Phase 1

Sirolimus and Cetuximab in Advanced Malignancies

NCT00940381
COMPLETED Phase 1

The Impact of Obesity and Obesity Treatments on Breast Cancer

NCT00933309
COMPLETED

Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

NCT00949390
COMPLETED Phase 1

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

NCT00941499
COMPLETED Phase 2

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

NCT00883688
COMPLETED Phase 2

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

NCT00942734
TERMINATED Phase 2

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT00941928
TERMINATED Phase 2

Outpatient Neutropenic Diet Study

NCT00947648
COMPLETED NA

Enhanced Smoking Cessation for University Students

NCT00941395
COMPLETED Phase 2

Xeloda (Capecitabine) and External Beam Radiation

NCT00916578
COMPLETED Phase 2

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

NCT00936936
COMPLETED Phase 2

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

NCT00915005
COMPLETED Phase 1

STAT3 Inhibitor for Solid Tumors

NCT00955812
COMPLETED Phase 1

A Pilot Study of Bevacizumab for Neoplastic Meningitis

NCT00924820
TERMINATED

Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy

NCT00925405
TERMINATED Phase 2

Obatoclax for Systemic Mastocytosis

NCT00918931
TERMINATED Phase 2

Personalized Treatment Selection for Metastatic Breast Cancer

NCT00780676
COMPLETED

Male:Female Birth Ratios and Phthalate Levels

NCT00903318
TERMINATED Phase 1

Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

NCT00895960
TERMINATED Phase 2

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

NCT00899431
COMPLETED

Self Reported Deviations From Opioid Analgesic Prescription

NCT00907192
COMPLETED Phase 3

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

NCT00904995
TERMINATED Phase 2

Sunitinib Malate in Refractory Germ Cell Tumors

NCT00912912
TERMINATED Phase 2

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

NCT00901927
TERMINATED

Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis

NCT00798187
TERMINATED Phase 1

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

NCT00831493
COMPLETED Phase 3

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

NCT00887068
COMPLETED Phase 1

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

NCT00880074
COMPLETED NA

Prostate Conformal Cryotherapy

NCT00877682
COMPLETED Phase 2

Acupuncture for Chemo-Induced Peripheral Neuropathy

NCT00891618
COMPLETED Phase 2

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

NCT00882102
COMPLETED Phase 1

Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)

NCT00832715
COMPLETED Phase 3

A Study for Leukemia Patients With Life-Threatening Infections

NCT00968838
COMPLETED NA

Comparison of Endobronchial Ultrasound-Guided Biopsy Using Fine Needle Aspiration Versus Fine Needle Capillary Sampling

NCT00886847
COMPLETED Phase 1

Erlotinib in Combination With Cetuximab

NCT00895362
COMPLETED Phase 1

Study of Erlotinib in Combination With Dasatinib

NCT00895128
COMPLETED Phase 1

Study of Erlotinib in Combination With Bortezomib

NCT00895687
COMPLETED Phase 1

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

NCT00903734
← Previous Page 39 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.